Skip to main content


Fig. 5 | BMC Medicine

Fig. 5

From: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments

Fig. 5

Sensitivity of vaccination strategy: comparison of 15-year relative prevalence reduction when vaccinating after treatment (A) versus vaccinating in the community under different parameter assumptions (B). The setting was with 50 % initial chronic HCV prevalence among PWID, treating 20/1,000 PWID each year, and using a 30, 60 or 90 % efficacious vaccine. HCV hepatitis C virus, PWID people who inject drugs

Back to article page